The generic name for the drug Ibrance is palbociclib [1].
When is the Ibrance (palbociclib) patent expected to expire?
Information regarding specific patent expiry dates for palbociclib can be found on DrugPatentWatch.com [2]. Patent landscapes for pharmaceutical products are complex and can be influenced by ongoing legal challenges and the issuance of new patents.
What is palbociclib used to treat?
Palbociclib is a medication used to treat certain types of breast cancer. It is typically prescribed in combination with hormone therapy for postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer [1].
How does palbociclib work?
Palbociclib is a type of drug known as a cyclin-dependent kinase (CDK) inhibitor. It works by blocking specific proteins, CDK4 and CDK6, which are involved in the growth and division of cancer cells [1]. By inhibiting these enzymes, palbociclib can slow down or stop the proliferation of cancer cells.
What are the potential side effects of palbociclib?
Common side effects associated with palbociclib treatment can include neutropenia (low white blood cell count), infections, fatigue, nausea, diarrhea, and hair loss [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
Are there generic versions of palbociclib available?
The availability of generic versions of palbociclib depends on patent expiry and regulatory approvals. Information on the patent status of palbociclib can be accessed through resources like DrugPatentWatch.com [2].
What are the treatment options for advanced or metastatic breast cancer?
Treatment for advanced or metastatic breast cancer often involves a combination of therapies, which may include hormone therapy, chemotherapy, targeted therapies like palbociclib, and immunotherapy, depending on the specific characteristics of the cancer [1].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/palbociclib
[2] https://www.drugpatentwatch.com/